CTOs on the Move


 
People come to Murad when they`re ready to transform the life of their skin. Murad guarantees that transformation because only Murad combines advanced scientific research and practical clinical experience to create high performance skincare products, dietary supplements and lifestyle programs that help people look and feel their absolute best. As America`s first authentic doctor-developed brand, Murad remains true to the scientific principles of its founder, world-renowned dermatologist Howard Murad, M.D. Shaped by his Inclusive Health philosophy and inspired by the real problems of the more than 50,000 patients and clients who have visited his Los Angeles dermatology practice and Inclusive Health ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.murad.com
  • 2141 Rosecrans Ave #6100
    El Segundo, CA USA 90245
  • Phone: 310.335.1700

Executives

Name Title Contact Details

Similar Companies

Lescarden

Lescarden is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

insurancecompany.com

insurancecompany.com is a Harbor City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MediMedia, Inc

MediMedia, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in San Bruno, CA. To find more information about MediMedia, Inc, please visit www.medimedia.com

Crothall Services Group

Crothall provides optimal laundry and linen services, both in the laundries that we own as well as those that we manage and operate. It is our depth of management expertise, along with our unyielding commitment to quality and customer service, which has

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.